Program Description
The expanding indications and emerging data for biologic therapies present new opportunities and challenges in the treatment of pediatric patients with moderate to severe atopic dermatitis (AD). As additional evidence supporting the use of biologic therapy in the treatment of pediatric AD becomes available, it will be imperative that pharmacists are educated on the use of these agents. Expert panelists will discuss the multifaceted roles of pharmacists in addressing quality of life considerations and treatment challenges affecting the management of therapies for pediatric patients with moderate to severe AD. The discussion by the multidisciplinary panel will also center on caregiver education strategies, including treatment expectations and importance of adherence to biologic therapy in improving clinical outcomes and quality of life. Included patient case examples demonstrate best practices for making clinical recommendations on the use of biologic therapies and in providing patient and caregiver communication for comprehensive management of pediatric patients with moderate to severe AD.
Target audience: Retail and specialty pharmacists
Type of activity: Application
Release date: January 31, 2024
Expiration date: January 31, 2025
Time to complete activity: 1.5 hours
Learner level: Foundational; Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the pathophysiology, clinical and economic burden, and impact of moderate to severe atopic dermatitis (AD) on quality of life for children and caregivers
- Analyze the efficacy and safety data of biologic therapies for the management of moderate to severe AD
- Identify effective medication management and patient counseling strategies to improve outcomes in patients with moderate to severe AD
JiaDe (Jeff) Yu, MD, MS
Assistant Professor of Dermatology
Director of Occupational and Contact Dermatitis
Associate Director of Clinical Unit for Research and Trials in Skin
Department of Dermatology
Massachusetts General Hospital, Harvard Medical School
Boston, Massachusetts
Allison P. Johnston, PharmD, BCPS, BCPPS
Associate Professor of Pharmacy Practice
Department of Pharmacy and Pharmaceutical Sciences
Lipscomb University
Nashville, Tennessee
Khalid M. Kamal, MPharm, PhD
Professor and Chair
Department of Pharmaceutical Systems and Policy
West Virginia University School of Pharmacy
Morgantown, West Virginia
Ashley W. Ellis, PharmD, MBA, CDECS
Assistant Dean for Strategic Partnerships & Innovation
University of Tennessee Health Science Center College of Pharmacy
Director of Practice Implementation
Tennessee Population Health Consortium
University of Tennessee Health Science Center College of Medicine
Medical Writer for Panel Discussion
Madison C. Ahlstrom, PharmD, MBA, RPh
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-005-H01-P. The activity is available for CE credit through January 31, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
JiaDe (Jefff) Yu, MD, MS, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: Dermatology Foundation, Pediatric Dermatology Research Alliance
Consultant: Arcutis, Sanofi, Incyte, National Eczema Association, O’Glacée, iRhythm
Khalid M. Kamal, MPharm, PhD, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: Cerevel Therapeutics, EMD Serono
Consultant: Pfizer/Cytel
Ashley W. Ellis, PharmD, MBA, CDECS, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: Researcher AHRQ “Tennessee Heart Health Network” funding in form of salary release dollars
Consultant: Global Parents for Eczema Research, Continuing Education Alliance, McGraw Hill
Allison P. Johnston, PharmD, BCPS, BCPPS, has no relevant financial relationships with commercial interests to disclose.
Medical Writer for Panel Discussion
Madison C. Ahlstrom, PharmD, MBA, RPh, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here